Search

Agios Pharmaceuticals Inc

Open

SectorGezondheidszorg

33.39 -0.12

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

32.22

Max

33.83

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.6M

-101M

Verkoop

24M

45M

EPS

-1.69

Winstmarge

-225.06

Werknemers

539

EBITDA

-11M

-109M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+23.48% upside

Dividenden

By Acuity

Volgende Winsten

29 okt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-253M

1.9B

Vorige openingsprijs

33.51

Vorige sluitingsprijs

33.39

Nieuwssentiment

By Acuity

34%

66%

104 / 340 Rangschikking in Healthcare

Agios Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 aug 2026, 20:01 UTC

Agios Pharmaceuticals Inc shares are higher today amid unusually high trading volume. The stock has gained significantly since Tuesday's close.

11 aug 2026, 19:26 UTC

Agios Pharmaceuticals Inc shares are higher today, with no specific news driving the move. Market focus remains on upcoming U.S. inflation reports.

10 aug 2026, 21:01 UTC

Agios Pharmaceuticals Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains below its 20-day moving average.

6 aug 2026, 19:32 UTC

Agios Pharmaceuticals shares are higher today, continuing an upward trend since Wednesday. The stock peaked earlier in the session before a slight pullback.

5 aug 2026, 19:56 UTC

News

Agios Pharmaceuticals is under investigation regarding its decision on tebapivat, contributing to lower trading activity today amid ongoing investor concerns.

4 aug 2026, 20:02 UTC

Agios Pharmaceuticals Inc shares are higher today amid broader market gains, supported by falling crude oil prices and comments on potential peace talks with Iran.

3 aug 2026, 20:06 UTC

Agios Pharmaceuticals Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

31 jul 2026, 22:51 UTC

Agios Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market declines amid mixed tech earnings and rising U.S. Treasury yields.

30 jul 2026, 20:08 UTC

Agios Pharmaceuticals shares are lower today amid mixed economic signals and unusually high trading volume. The stock has declined since Wednesday's close.

29 jul 2026, 20:51 UTC

Agios Pharmaceuticals Inc shares gained in after-market trading, rebounding from a session low despite broader market pressures from rising crude oil prices and geopolitical tensions.

28 jul 2026, 20:02 UTC

News

Agios Pharmaceuticals shares are lower amid an investigation into potential claims following the halted development of tebapivat for sickle cell disease.

27 jul 2026, 20:01 UTC

Agios Pharmaceuticals Inc shares are higher during Monday's session, reaching a notable peak earlier in the day. No specific news was identified for the move.

24 jul 2026, 23:21 UTC

Agios Pharmaceuticals shares are higher in after-market trading, supported by a decline in initial jobless claims, indicating a robust labor market.

22 jul 2026, 22:41 UTC

Agios Pharmaceuticals shares are lower in after-market trading, continuing a three-session decline amid broader market concerns over rising crude oil prices and inflation.

21 jul 2026, 19:01 UTC

News
Event
Social Media

Agios Pharmaceuticals shares declined after discontinuing tebapivat development for sickle cell disease, despite some trial improvements. The stock remains lower since Monday's close.

Peer Vergelijking

Prijswijziging

Agios Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

23.48% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 41.33 USD  23.48%

Hoogste 55 USD

Laagste 31 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Agios Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

9 ratings

6

Buy

3

Hold

0

Sell

Sentiment

By Acuity

104 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat